Novo Nordisk A/S
Stock Forecast, Prediction & Price Target
Novo Nordisk A/S (NVO) stock Price Target by analysts
$156
Potential upside: 187.18%
Novo Nordisk A/S price prediction
What is Novo Nordisk A/S stock analysts` prediction?
Novo Nordisk A/S stock forecast: Based on 1 Wall Street analysts` predicted price targets for Novo Nordisk A/S in the last 3 months, the avarage price target is $156, with a high forecast of $NaN. The average price target represents a 187.18% change from the last price of $54.32.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Novo Nordisk A/S stock Price Target by analysts
Full breakdown of analysts given Novo Nordisk A/S price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Evan Seigerman BMO Capital | 0% 0/1 | 11 months ago | $156 187.18% upside | $118.58 | TheFly | Previous targets (0) |
Louise Chen Cantor Fitzgerald | 0% 0/1 | about 1 year ago | $160 194.55% upside | $135.23 | StreetInsider | Previous targets (0) |
Evan David Seigerman BMO Capital | 0% 0/2 | about 1 year ago | $160 194.55% upside | $126.17 | StreetInsider | Previous targets (1) |
Jasper Hellweg Argus Research | 0% 0/1 | over 1 year ago | $160 194.55% upside | $142.88 | TheFly | Previous targets (0) |
James Quigley Goldman Sachs | 0% 0/1 | over 1 year ago | $156 187.18% upside | $132.68 | TheFly | Previous targets (0) |
Evan David Seigerman BMO Capital | 0% 0/2 | over 1 year ago | $163 200.07% upside | $125.4 | StreetInsider | Previous targets (1) |
Novo Nordisk A/S Financial Estimates
Novo Nordisk A/S Revenue Estimates
Novo Nordisk A/S EBITDA Estimates
Novo Nordisk A/S Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $140.8B N/A | $176.95B 25.67% | $232.26B 31.25% | Avg: $345.97B Low: $340.05B High: $349.40B avg. 48.96% | Avg: $400.09B Low: $378.71B High: $417.81B avg. 15.64% | Avg: $439.67B Low: $416.17B High: $459.14B avg. 9.89% | Avg: $483.42B Low: $457.58B High: $504.83B avg. 9.95% |
Net Income
% change YoY
| $47.75B N/A | $55.52B 16.26% | $83.68B 50.71% | Avg: $128.13B Low: $112.04B High: $138.56B avg. 53.12% | Avg: $152.59B Low: $141.99B High: $161.38B avg. 19.08% | Avg: $165.91B Low: $154.38B High: $175.46B avg. 8.72% | Avg: $181.98B Low: $169.33B High: $192.45B avg. 9.68% |
EBITDA
% change YoY
| $67.55B N/A | $82.04B 21.43% | $114.62B 39.72% | Avg: $164.52B Low: $161.70B High: $166.14B avg. 43.52% | Avg: $190.25B Low: $180.08B High: $198.68B avg. 15.64% | Avg: $209.07B Low: $197.90B High: $218.33B avg. 9.89% | Avg: $229.88B Low: $217.59B High: $240.06B avg. 9.95% |
EPS
% change YoY
| $10.4 N/A | $12.26 17.88% | $18.62 51.87% | Avg: $28.51 Low: $24.93 High: $30.83 avg. 53.10% | Avg: $33.95 Low: $31.59 High: $35.9 avg. 19.08% | Avg: $36.91 Low: $34.35 High: $39.04 avg. 8.72% | Avg: $40.49 Low: $37.67 High: $42.82 avg. 9.68% |
Operating Expenses
% change YoY
| $58.49B N/A | $73.69B 25.98% | $93.92B 27.44% | Avg: $98.77B Low: $97.08B High: $99.74B avg. 5.16% | Avg: $114.22B Low: $108.11B High: $119.28B avg. 15.64% | Avg: $125.52B Low: $118.81B High: $131.07B avg. 9.89% | Avg: $138.01B Low: $130.63B High: $144.12B avg. 9.95% |
FAQ
What is Novo Nordisk A/S stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 22.65% in 2025-2028.
We have gathered data from 7 analysts. Their low estimate is 112.04B, average is 128.13B and high is 138.56B.
What is Novo Nordisk A/S stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 21.11% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $340.05B, average is $345.97B and high is $349.40B.
What is Novo Nordisk A/S stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 22.65% in 2025-2028.
We have gathered data from 7 analysts. Their low earnings per share estimate is $24.93, average is $28.51 and high is $30.82.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Novo Nordisk A/S stock. The most successful analyst is Evan Seigerman.